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B I O P H Y S I C S
Small-molecule sequestration of amyloid- as a drug 
discovery strategy for Alzheimer’s disease
Gabriella T. Heller1, Francesco A. Aprile1,2, Thomas C. T. Michaels1,3, Ryan Limbocker1*, 
Michele Perni1, Francesco Simone Ruggeri1, Benedetta Mannini1, Thomas Löhr1, 
Massimiliano Bonomi4, Carlo Camilloni5, Alfonso De Simone6,7, Isabella C. Felli8,9, 
Roberta Pierattelli8,9, Tuomas P. J. Knowles1, Christopher M. Dobson1, Michele Vendruscolo1†
Disordered proteins are challenging therapeutic targets, and no drug is currently in clinical use that modifies the 
properties of their monomeric states. Here, we identify a small molecule (10074-G5) capable of binding and se-
questering the intrinsically disordered amyloid-β (Aβ) peptide in its monomeric, soluble state. Our analysis re-
veals that this compound interacts with Aβ and inhibits both the primary and secondary nucleation pathways in 
its aggregation process. We characterize this interaction using biophysical experiments and integrative structural 
ensemble determination methods. We observe that this molecule increases the conformational entropy of mono-
meric Aβ while decreasing its hydrophobic surface area. We also show that it rescues a Caenorhabditis elegans 
model of Aβ-associated toxicity, consistent with the mechanism of action identified from the in silico and in vitro 
studies. These results illustrate the strategy of stabilizing the monomeric states of disordered proteins with small 
molecules to alter their behavior for therapeutic purposes. 
INTRODUCTION
Alzheimer’s disease is a fatal neurodegenerative condition and the 
leading cause of dementia, which affects more than 50 million people 
worldwide, a number that is predicted to rise to 150 million by 2050 
unless methods of prevention or treatment are found (1). Despite 
over 25 years of intensive research and hundreds of clinical trials, 
there is still no drug capable of modifying the course of this disease (1).
The aggregation of the amyloid- (A) peptide in brain tissue is 
one of the hallmarks of Alzheimer’s disease (2). This process in-
volves at least three forms of A: (i) a monomeric state, which is 
highly disordered; (ii) oligomeric aggregates, which are heteroge-
neous, transient, and cytotoxic; and (iii) fibrillar structures, which 
are ordered and relatively inert, although they are capable of cata-
lyzing the formation of A oligomers (3). More generally, the aggrega-
tion of A involves a complex nonlinear network of interdependent 
microscopic processes, including (i) primary nucleation, in which 
oligomers form from monomeric species; (ii) elongation, in which 
oligomers and fibrils increase in size by monomer addition; (iii) sec-
ondary nucleation, whereby the surfaces of fibrillar aggregates catalyze 
the formation of new oligomeric species; and (iv) fragmentation, in 
which fibrils break into smaller pieces, increasing the total number 
of oligomers and fibrils capable of elongation (2).
A is produced by proteolysis from the transmembrane amyloid 
precursor protein, and its 42-residue form (A42) is the predominant 
species in deposits characteristically observed in the brains of patients 
with Alzheimer’s disease (4). Kinetic analysis shows that, once a 
critical concentration of A42 fibrils has been formed, secondary 
nucleation overtakes primary nucleation in becoming the major 
source of A42 oligomers, as fibril surfaces act as catalytic sites for 
their formation (3). The fact that the oligomers appear to be the most 
toxic species formed during the aggregation process (5, 6), however, 
suggests that therapeutic strategies targeting A aggregation should 
not primarily aim at inhibiting fibril formation per se, but rather 
doing so in a manner that specifically reduces the generation of 
oligomeric species (2). Complex feedback mechanisms between the 
different microscopic steps in the aggregation reaction can lead to 
an increase in the concentration of oligomers even when the forma-
tion of fibrils is inhibited and hence result in an increase in patho-
genicity (2).
Previous studies have suggested that effective strategies for in-
hibiting A aggregation could be based on targeting fibril surfaces 
to suppress the generation of oligomers or the reduction of the tox-
icity of the oligomers (7–11). It is unclear, however, whether seques-
tering A in its soluble state could be an effective drug discovery 
strategy against Alzheimer’s disease. Stabilization of monomeric A 
into a -hairpin conformation with large biomolecules has been 
previously demonstrated to inhibit aggregation, for example, using 
an affibody protein (12). However, whether this stabilization of A 
in its monomeric form can be achieved via small-molecule binding 
in a drug-like manner is still under debate. While there is research 
indicating a stabilizing effect of small molecules on the soluble state 
of A, there are contradictory reports of their effects on its aggrega-
tion (13–15). It should also be considered that these molecules may 
not be specific, as for example, some appear to bind monomeric A 
in a manner similar to low concentrations of SDS (13–15). Further-
more, it has been proposed that the binding of these small molecules 
to monomeric A may be mediated by colloidal particles formed by 
the small molecules (16), although this observation has also been 
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disputed (13, 14). The uncertainty of whether monomeric A is a 
viable drug target is caused, in part, by a lack of understanding of 
the molecular properties of monomeric A and how to stabilize this 
peptide with specific small molecules that have the potential to be 
developed as drugs.
A, in its monomeric form, is intrinsically disordered, as it lacks 
a well-defined structure and instead exists as a heterogeneous en-
semble of conformationally distinct states (17). The dynamic nature 
of disordered proteins, and the consequent absence of stable and 
persistent binding pockets, implies that they do not readily lend 
themselves to conventional, enthalpy focused mechanisms of drug 
binding, such as the well-established lock-and-key paradigm, in which 
a drug fits snugly into a single, well-defined binding site (18, 19). As 
a result, targeting disordered proteins with small molecules has not 
been considered a promising drug discovery strategy, and there are 
no small molecules on the market directly targeting disordered re-
gions despite their high prevalence in disease. Recently, it has been 
proposed that it may be possible to bind disordered proteins with 
small molecules via the entropic expansion mechanism, in which 
the conformational entropy of the disordered protein increases upon 
binding a small molecule (18), although until now, this has yet to be 
demonstrated. A deeper understanding of the possible mechanisms 
by which small molecules can modify the behavior of disordered 
proteins may open new avenues for drug development, not only 
against Alzheimer’s disease and other neurodegenerative disorders 
but also many other medical conditions involving disordered pro-
teins, including type 2 diabetes, certain forms of cancer, and 
cardiovascular disease (17, 18). This insight may also be particularly 
valuable in modulating liquid-liquid phase separation, which often 
involves protein disorder (20).
Using experimental and computational biophysical techniques 
and mathematical modeling, we characterize the interaction of the 
small-molecule 10074-G5 [biphenyl-2-yl-(7-nitro-benzo[1,2,5]
oxadiazol-4-yl)-amine; Fig. 1A], with A42 in its disordered, mono-
meric state. 10074-G5 has been previously identified to inhibit c-Myc-
Max heterodimerization (21), specifically by binding and stabilizing 
the intrinsically disordered c-Myc monomer (22, 23). Here, we also 
observe that 10074-G5 binds monomeric A42, a disordered peptide 
unrelated to c-Myc. As a result of this interaction, 10074-G5 signifi-
cantly delays both primary and secondary nucleation pathways in 
A42 aggregation. We characterize this interaction using biophysical 
experiments and integrative structural ensemble determination 
techniques and observe that A42 remains disordered in the bound 
form with decreased hydrophobicity. Notably, we also observe that 
the conformational entropy of A42 increases upon interacting with 
10074-G5 via the entropic expansion mechanism, suggesting that 
exploiting this phenomenon may be a potential therapeutic strategy 
for disordered proteins. We further show that this molecule inhibits 
the paralysis associated with A42 aggregation in a Caenorhabditis 
elegans muscle model of A42-mediated toxicity in a manner con-
sistent with the binding mechanism described in silico and charac-
terized in vitro.
RESULTS
Selection of the system
We selected the compound 10074-G5 as model system to under-
stand whether and how a small molecule inhibits the aggregation of 
A by binding the monomeric form of this peptide. We used this 
molecule as it has been reported to bind another disordered protein 
in its monomeric form, the oncogenic c-Myc, and it contains a 
nitrobenzofurazan moiety, which has been previously shown to 
inhibit the aggregation of A (24).
Characterization of the binding of 10074-G5 to 
monomeric A42
We characterized the binding of 10074-G5 with monomeric A42 
using a multidisciplinary approach based on experiments and in-
tegrative structural ensemble determination. First, we carried out 
biolayer interferometry (BLI; see Materials and Methods) measure-
ments to characterize this interaction in real time. We immobilized 
N-terminally biotinylated monomeric A42 on the surface of super 
streptavidin sensor tips (Materials and Methods) and exposed them 
to varying concentrations of the small molecule (Fig. 1B and fig. S1). 
We observed a concentration-dependent response, indicative of bind-
ing. We globally fit the binding curves to simple one-step association 
and dissociation equations such that the fit constrains all curves to 
share single association (kon) and dissociation (koff) rates, with a global 
R2 (coefficient of determination) value of 0.98. From these fits, we 
determined kon to be 8.5 × 103 ± 0.2 × 103 M−1 s−1 and koff to be 
4.7 × 10−2 ± 2 × 10−4 s−1, corresponding to a binding dissociation 
constant (Kd) of 6 M. This affinity value is comparable to other 
small-molecule interactions with disordered proteins (22), although 
we note that constraining disordered monomeric A42 to a surface 
may perturb the binding that occurs as compared to the uncon-
strained peptide in solution.
We then investigated the binding of 10074-G5 and monomeric 
A42 at the ensemble-averaged, single residue level. To do so, we 
performed 2D HN–BESTCON nuclear magnetic resonance (NMR) 
experiments (25) on uniformly 13C, 15N-labeled monomeric A42 in 
the presence of one- and twofold concentrations of 10074-G5. As 
monomeric A42 is relatively stable in solution at low concentrations 
and temperatures, we examined the binding of 10074-G5 to mono-
meric A42 under these conditions (20 M A42 at 5°C). Minimal 
chemical shift perturbations were observed in the 2D HN–BESTCON 
spectra upon the addition of compound at a 2:1 ligand:protein ratio 
at 5°C (fig. S2A), consistent with other reports of small-molecule 
binders of disordered proteins (22, 26), suggesting that A42 remains 
disordered in the presence of 10074-G5. We then performed this 
experiment at 15°C in the absence and presence of presaturation of 
the solvent. This experiment, which relies on heteronuclear direct 
detection with minimal perturbation of proton polarization, provides 
a valuable tool to study solvent exposed systems in which amide 
protons experience fast hydrogen exchange (25). In particular, the 
signals of amide nitrogen atoms become attenuated when their di-
rectly bound protons are in fast exchange with the solvent. After 
testing this on a well-characterized protein (ubiquitin), we performed 
this experiment on A42 (Fig. 1C). In the absence of 10074-G5, we 
observed that several hydrophobic residues, particularly C-terminal 
residues, are protected from solvent exchange (Leu17, Leu34, Val36, 
Ile41, and Ala42; see I/I0 values as shown in Fig. 1D). Notably, in the 
presence of 10074-G5, we observed the quenching of several resi-
dues across the sequence of the monomeric A42 peptide that were 
not quenched in the absence of 10074-G5 (Glu3, Phe4, Val12, His13, 
Ala21, Asp23, Val24, Leu34, and Val36; see I/I0 values as shown in 
Fig. 1D), suggesting that some residues have increased solvent expo-
sure in the presence of the small molecule. This change in the solvent 
exchange profile suggests that 10074-G5 interacts with monomeric 
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A42 in a manner that increases the solubility of at least some of the 
conformations within the monomeric structural ensemble (18).
To obtain further insight into the thermodynamic properties of this 
interaction, we quantified the heat changes upon 10074-G5 binding 
to A40 using isothermal titration calorimetry methods (fig. S2, B 
and C). In these experiments, we used A40 instead of A42 because 
of the higher solubility of A40; we have, however, shown that 10074-
G5 has similar effects on the aggregation of A40 as on that of A42 
(fig. S3A). The observation of minimal heat changes (fig. S2, B and C) 
suggests that the interaction of 10074-G5 with monomeric A has 
minimal enthalpy and is thus likely to be entropic, as found for the 
interactions of another small molecule with a disordered peptide (27).
To obtain a structural description of how 10074-G5 affects the 
disordered structural ensemble of A42, we used metadynamic me-
tainference, an integrative structural ensemble determination ap-
proach (28, 29) that combines all-atom molecular dynamics simula-
tions with NMR chemical shift data to improve force field accuracy 
(see Materials and Methods, Figs. 2 and 3, and figs. S4 to S6). These 
simulations reveal that A42 remains disordered in the form bound 
to 10074-G5, retaining several ensemble-averaged properties. Within 
this fuzzy interaction (30), we noted that most average inter-residue 
contacts of the unbound peptide remain the same in the bound form 
(Fig. 2A). Furthermore, the distributions (Fig. 2B) and average values 
(apo, 1.146 ± 0.002 nm; holo, 1.116 ± 0.004 nm) of the radii of gyration 
of the bound and unbound forms of the peptide are also highly similar. 
The presence of 10074-G5 does, however, alter the conformational 
ensemble of A42, promoting conformations with lower relative 
hydrophobic surface area (the fraction of accessible hydrophobic 
Fig. 1. Characterization of the interaction of 10074-G5 with monomeric A42. (A) Structure of biphenyl-2-yl-(7-nitro-benzo[1,2,5]oxadiazol-4-yl)-amine, also known 
as 10074-G5. (B) Biolayer interferometry measurements showing the dose-dependent binding of 10074-G5 to an A42-functionalized surface at various concentrations of 
the added compound. The curves were corrected for baseline drift. Raw data are shown in fig. S1A. Control curves showing negligible nonspecific binding are shown in fig. S1 
(B and D). Global fitting to simple one-phase association and dissociation equations yields association (kon) and dissociation (koff) rates to be 8.5 × 103 ± 0.2 × 103 M−1 s−1 
and 4.7 × 10−2 ± 2 × 10−4 s−1, respectively, corresponding to a binding dissociation constant (Kd) of 6 M. For this fit, all five curves were constrained to single, shared kon 
and koff values. The global R2 for the fits is 0.98. (C) 2D HN–BESTCON spectra in the absence (left) and presence (right) of 1:2 A42:10074-G5 with (red) and without (gray) 
selective water presaturation, performed at 15°C. (D) Quantification of the relative I/I0 intensities from (C) shows that the peptide amide groups are more exposed to 
solvent in the presence of 10074-G5 (blue) as compared to its absence (gray). Arrows highlight regions along the sequence in which signals are detectable in the ab-
sence of the compound, but not in its presence, thus suggesting that 10074-G5 increases the solvent exposure of specific regions of A42. ppm, parts per million.
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surface area with respect to the total accessible surface area; Fig. 2C). 
To determine which residues became more exposed or protected in 
the presence of 10074-G5, we compared the average solvent acces-
sible surface areas per residue in the presence and absence of 10074-
G5 (Fig. 2D). Notably, we observe that Leu34 and Met35 become 
more protected in the presence of the small molecule. Met35 has pre-
viously been identified as a key residue for attenuation of aggrega-
tion, as oxidation has been shown to reduce the lag time of primary 
nucleation (31). These data from the simulation represent distribu-
tions and averages of the conformational ensembles. While Fig. 1D 
experimentally quantifies residue-specific changes in solvent expo-
sure, the result is both ensemble and time averaged over the duration 
of the measurement and cannot be quantitively compared to residue- 
specific average solvent accessible surface areas calculated from these 
equilibrium simulations (Fig. 2D), as these results are not time averaged.
The decrease in the hydrophobic surface area of A42 prompted 
us to investigate the role of water in the binding interaction. To this 
end, we calculated the average number of hydrogen bonds formed 
by water molecules within the hydration shell (all waters within 
0.4 nm of A42). We found that water molecules form 3.07509 ± 
0.00004 hydrogen bonds on average in the absence of 10074-G5, a 
number that increases in its presence to 3.0959 ± 0.0005, getting closer 
to the bulk-like values of 3.44801 ± 0.00002 and 3.44791 ± 0.00002, 
for apo and holo systems, respectively, under the conditions inves-
tigated here; errors are calculated comparing the first and second 
halves of the trajectories (fig. S6A) (32). As expected, we ob-
served little difference between the average number of hydrogen 
bonds formed by water molecules in the bulk between the apo and 
holo simulations (fig. S6B). To determine whether or not this bind-
ing could be characterized by the release of water molecules upon 
Fig. 2. Metadynamic metainference simulations characterize the dynamic binding and show how 10074-G5 promotes A42 conformations with less hydropho-
bicity. (A) Metadynamics metainference simulations demonstrate that inter-residue contact maps for Lennard-Jones (LJ) (top right) and Coulomb (top left) potentials for 
the unbound (orange) and the bound (green) structural ensembles of A42 with 10074-G5 are highly similar. (B) Radii of gyration for the unbound and bound structural 
ensembles are also highly similar (shown using kernel density estimates of 35,000 points each sampled based on metadynamics weights using a Gaussian kernel). (C) Relative 
hydrophobic solvent accessible surface area (SASA) of A42 (total hydrophobic area over total surface area) of the bound and unbound ensembles, showing that 10074-G5 
decreases the relative exposed hydrophobicity of A42. The holo ensemble was calculated only on the protein surface but accounts for the presence of the compound. 
Data are shown using kernel density estimates as described in (B). Some of the representative structures from these distributions are shown. Numbers indicate cluster IDs 
shown in Fig. 3. (D) Ratio (bound/unbound) of the ensemble-averaged, total SASA per residue showing regions of A42 that become more exposed or protected in the 
presence of 10074-G5. SASAs of the bound ensemble were calculated on the protein in the presence of 10074-G5. (E) Ensemble-averaged, residue-specific LJ and 
Coulomb interaction energies show that 10074-G5 has strong interactions with aromatic and charged residues. Error bars represent SDs between first and second halves 
of the analyzed trajectories in (D) and (E).
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association, we calculated the average number of water molecules 
in the hydration shell and show that this value is similar with and 
without association (fig. S6C).
Given the lack of experimental evidence for enthalpic contribu-
tions to the binding, we investigated whether or not we could detect 
entropic signatures of binding. Previously, changes in conformational 
entropy have been estimated from probability distributions of struc-
tural parameters, such as the radius of gyration (33). Given the sim-
ilarity of the radius of gyration in the bound and unbound forms of the 
peptide (Fig. 2B), to increase the sensitivity, we applied this approach 
to the residue-specific Ramachandran plots (Fig. 3A), finding that 
for the majority of nonterminal residues, the entropy increases in the 
bound form of the peptide. Nevertheless, quantifying the total change 
in the conformational entropy of A42 in the presence and absence 
of 10074-G5 using this approach is challenging given the correlated 
nature of consecutive dihedral angles. To unequivocally quantify the 
differences in conformational entropy of the peptide upon binding 
the small molecule, structurally characterize the unbound and bound 
conformations of A42, and assess convergence, we performed a 
clustering analysis (Fig. 3, B and C, and fig. S6D). In particular, con-
sidering only A42, we combined the bound and unbound trajectories 
and grouped them into states based on inter-residue Lennard-Jones (LJ) 
interaction energies per frame using the GROMOS clustering algo-
rithm (see the Supplementary Materials) (34). We observed that while 
10074-G5 binds the extended form (state 0) in a nonspecific manner, 
all other structural clusters show localization of the compound within 
well-defined pockets of A42 for specific conformations (Figs. 2C and 
3B) involving hydrophobic, hydrophilic, charged, and polar residues 
(fig. S6D). On the basis of the clustering analysis, we calculated the 
conformational entropy of A42 in the bound and unbound form 
(see eq. S10 and Fig. 3D). We observed that the conformational en-
tropy of the peptide increased in the bound form, suggesting that 
Fig. 3. 10074-G5 increases the conformational entropy of A42. (A) Residue-specific differences in the conformational entropies, S, between the holo and apo ensem-
bles, estimated from normalized, two-dimensional (2D) Ramachandran histograms (100 × 100 bins) of each residue using S = − Σ b ln b where b is the occupancy of a 
given bin. (B) Donut plots quantifying the conformational states of A42 in the unbound (left, orange) and bound (right, green) simulations. Clustering was performed on 
concatenated trajectories, considering only A42. Inter-residue contact maps based on the Lennard-Jones potential were used as input for GROMOS clustering (34). The 
cut-off value is 8.5 kJ mol−1. Each slice represents a distinct state. The simulations share one major state (cluster 0, gray), which comprises 18 and 31% of the unbound and 
bound ensembles, respectively. (C) Convergence of the five most populated clusters. Bar plot shows fractional cluster occupancies for the unbound (orange) and bound 
(green) simulations. Fractional cluster occupancies were calculated on 35,000 frames for each concatenated trajectory sampled based on metadynamics weights. (D) The 
conformational entropy of A42, estimated via Gibbs entropy, is consistently higher in the 10074-G5–bound form of the peptide for several clustering cut-off values. The 
conformational entropy was calculated such that the weights, P, of each state correspond to the fractional occupancy as determined by the GROMOS clustering algorithm 
(34). Error bars represent ± SDs of values calculated from the first and second halves of the simulations in (C) and (D).
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the interaction between A42 and 10074-G5 exhibits the entropic 
expansion mechanism, in which the entropy of the protein contributes 
favorably to the binding free energy (Fig. 3D) (18). Often, drug 
binding for folded proteins is described in terms of a lock-and-key 
binding mechanism, in which a protein is constrained by the binding 
of a small molecule, and therefore the entropy of the protein con-
tributes unfavorably to the free energy of binding. In stark contrast 
to this mechanism, in the entropic expansion mechanism, the pro-
tein becomes more disordered upon interacting with a small molecule, 
and thus the conformational landscape is expanded upon binding 
(18). The increase in conformational heterogeneity in the bound 
form of A42 upon binding 10074-G5 may explain the increase in 
solvation observed by NMR (Fig. 1, C and D). We hypothesize that 
the increased interconversion between states of A42 in the pres-
ence of 10074-G5 may result in a net exposure of the peptide to the 
solvent. Investigating this possibility, however, would entail further 
characterization, which is currently beyond the scope of the simula-
tions presented here; as in the metadynamics framework, we sacri-
fice dynamic information for improved sampling. Nevertheless, the 
observation of entropic expansion suggests that the identification 
of small molecules that increase the conformational entropy of 
the disordered proteins may be a promising therapeutic strategy for 
disordered proteins involved in aggregation.
To probe the energetic contributions to this interaction on an 
ensemble-averaged, residue-specific level, we analyzed Lennard- Jones 
and Coulomb contributions between 10074-G5 and each residue. 
We observe strong Lennard-Jones interactions, particularly between 
aromatic residues (Fig. 2E) Tyr10, Phe19 and Phe 20, and 10074-G5. 
The strongest Coulomb interactions occur at charged residues Lys16 
and Lys28 (Fig. 2E).
The small-molecule 10074-G5 sequesters monomeric A42 
and inhibits its aggregation
We measured the kinetics of A42 aggregation at a concentration of 
1 M in the absence and presence of increasing concentrations of 
10074-G5. Measurements were performed by means of a fluorescent 
assay based on the amyloid-specific dye thioflavin T (ThT), which 
reports on the overall fibril mass formed during the aggregation pro-
cess (3, 35–38). While the range of possible concentrations of A42 
and 10074-G5 were restricted for the NMR experiments due to a lack 
of sensitivity and limited solubilities of both A42 and 10074-G5, 
the high sensitivity of ThT enabled us to work with lower concen-
trations of A42 as compared to the NMR experiments and there-
by probe higher ligand:protein ratios. We found that 10074-G5 has 
a notable effect on A42 aggregation (Fig. 4, A and B). Specifically, 
the data show that the final value of the ThT fluorescence, which 
corresponds to the end point of the aggregation reaction, is depen-
dent on the concentration of the compound (Fig. 4A). The observa-
tion of a significant decrease in the final ThT intensity could be due 
to several nonmutually exclusive possibilities including (i) interference 
of the ThT signal by 10074-G5, (ii) formation of soluble off-pathway 
aggregates, and (iii) sequestration of A42 during the aggregation 
process (7).
Given the fact that 10074-G5 is a colored compound, we sought 
to investigate whether the decrease in the fluorescence intensity of 
ThT was exclusively due to an interference of 10074-G5 with the dye 
or also due to a decrease in the mass of the fibrils formed during the 
aggregation process. To this end, we performed a ThT-independent 
dot-blot assay in which we explicitly measured the quantity of solu-
ble A42 over 15 hours in the presence and absence of 10074-G5 using 
the W0-2 antibody, which binds to A (Fig. 4, C to E). The solubility 
was determined by measuring the amount of A42 that did not sedi-
ment after 1 hour of ultracentrifugation at 100,000 rpm. We observed 
that in the presence of a 20-fold excess of 10074-G5, approximately 
40% of the total amount of A42 remained in a soluble form (Fig. 4, 
D and E). These experiments indicate that not all A42 monomers 
are incorporated in ThT-binding fibrils at the end of the aggregation 
process and, thus, that the presence of 10074-G5 sequesters A42 in 
its soluble form. These dot-blot data can be explained by an equilib-
rium model of competitive binding, where monomers can bind both 
to amyloid fibril ends and to 10074-G5 (Materials and Methods; 
Fig. 4E). A fit of the dot-blot data to this equilibrium model (eq. S14) 
yields an affinity of 10074-G5 for the monomers of Kd = 7 ± 1 M, a 
value consistent with that determined independently from the BLI 
experiments (Kd = 6 M), especially considering that in the BLI set-
up A42 is constrained on a surface (Fig. 1B), whereas in the dot-blot 
measurement the binding occurs in solution. We further confirmed 
the observation that A42 remains soluble by exploiting the intrinsic 
fluorescence of Tyr10 in the A42 sequence. By monitoring the ag-
gregation of 5 M A42 from its monomeric form over 1 hour, the 
fluorescence intensity of Tyr10 increases considerably (Fig. 4F) as it 
becomes buried in a hydrophobic environment in the aggregated 
state (39). This experiment reports on early aggregation events that 
may be invisible to ThT, which is specific for cross– sheet content, 
as early aggregates such as oligomers or multimers may lack  sheet 
structure (40). We observed, however, that in the presence of an 
equimolar concentration of 10074-G5, the fluorescence intensity 
remains constant over time (Fig. 4G), thereby suggesting that A42 
does not self-associate in the presence of 10074-G5.
To further demonstrate that 10074-G5 alters the kinetics of aggre-
gation, we performed three-dimensional (3D) morphological analyses 
of fibrils using high-resolution and phase-controlled (41) atomic force 
microscopy (AFM) on the time scale of the aggregation process 
(Fig. 4B and fig. S7A). Single-molecule statistical analysis of the ag-
gregates in the 3D maps shows that A42, both in the absence and 
presence of 10074-G5, forms nonmature aggregates with average 
cross-sectional diameters of approximately 2 to 3 nm, and mature 
fibrillar aggregates with average diameters of approximately 5 to 6 nm, 
as previously observed (42, 43). It has been shown that fibrillar species 
with diameters less than 6 nm lack a complete (or mature) cross– 
sheet structure stabilized by a tight network of intermolecular hydro-
gen bonding, as compared to mature fibrillar aggregates (42). Notably, 
we observed that at the same time point of aggregation, the fibrillar 
aggregates formed in the presence of 10074-G5 had smaller cross- 
sectional diameters than those formed in its absence, with a signifi-
cantly higher abundance of nonmature species with respect to mature 
fibrillar species. These data suggest that the process of fibril forma-
tion and maturation of cross– sheet structure in the presence of this 
compound is considerably slower than in its absence (Fig. 4B and 
fig. S7A) (43).
10047-G5 does not chemically modify A42
To determine whether or not the binding of 10074-G5 to A42 is 
covalent or induces other chemical modifications, we performed mass 
spectrometry on A42 incubated in the presence and absence of 
10074-G5. Samples were incubated overnight at 37°C and then spun 
down using an ultracentrifuge (Materials and Methods). The superna-
tant and resuspended pellet of the aggregation reactions were analyzed 
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by matrix assisted laser desorption/ionization (MALDI) mass spec-
trometry (fig. S7B). No mass increase was observed following the 
incubation with 10074-G5, indicating that its presence does not re-
sult in detectable covalent chemical modifications to A42.
10074-G5 inhibits all microscopic steps of A42 aggregation
To better understand the mechanism of inhibition of A42 aggrega-
tion by 10074-G5, we performed a kinetic analysis on the ThT ag-
gregation traces. Figure 5A shows the ThT kinetic curves, and from 
the data, we observe that 10074-G5 slows down the aggregation re-
action in a concentration-dependent manner, consistent with the 
AFM results, confirming a delay in the aggregation process of A42 
(Fig. 4B and fig. S7A). Furthermore, our dot-blot analysis shows that 
a fraction of the total monomer concentration is left unreacted at 
the end of the aggregation reaction (Fig. 4, C to E). The simplest 
model that accounts both for the delay of aggregation and for the 
fact that not all A ends up in the fibrils is one in which monomer 
is effectively removed from the reaction by the inhibitor. The final 
load on fibrils depends on the amount of free monomer available 
for the reaction. Furthermore, reducing the pool of available mono-
mers slows down the rates of all aggregation steps, as monomers are 
involved in all microscopic steps.
Models of inhibition in which fibril surfaces or fibril ends are 
targeted by inhibitors would explain the delay in aggregation, but not 
the decrease fibril load (fig. S3D). By using explicit rate laws (38) for 
describing this inhibition model by monomer sequestration, we sought 
to understand whether our data could be explained by 10074-G5 
exclusively binding the monomer, and in this manner, reducing the 
concentration of monomers available for the overall aggregation reac-
tion and each microscopic step of aggregation (see the Supplementary 
Fig. 4. 10074-G5 sequesters monomeric A42 and inhibits its aggregation. (A) ThT measurements using 1 M A42 show concentration-dependent effects of 10074-
G5 on A42 aggregation. Measurements were taken in triplicate. The concentration of DMSO was held constant across all samples. (B) Distributions of cross-sectional 
heights of 1 M A42 fibrils at 2.5 hours (n ≥ 60) and 7.5 hours (n ≥ 200) formed with and without 6 M 10074-G5, from single-molecule analyses of AFM maps (fig. S7). 
Lines indicate means. P values were determined by unpaired, two-tailed Student’s t test. Fibrillar aggregates formed in the presence of 10074-G5 have smaller cross- 
sectional diameters than those formed in its absence. (C) Dot blot of soluble A42 before and after the aggregation of 1 M A42 with and without 10074-G5 using the W0-2 
antibody indicates sequestration of soluble A42. Blotting was performed in triplicate. Fit (D) and quantification (E) used to estimate the concentration of soluble A42 
remaining at the end of the aggregation reaction from (C). The dashed curve in (E) represents fit to eq. S14, describing the equilibrium concentration of unreacted mono-
mer from a competitive binding of free monomers to fibril ends and inhibitor. Using this simple fit, we determined the fitted affinity of 10074-G5 for the soluble material 
to be Kd = 7 ± 1 M. Intrinsic fluorescence profiles of Tyr10 of 5 M A42 in the absence (F) and presence (G) of 1:1 10074-G5 over 1 hour show that 10074-G5 delays an increase 
in fluorescence, suggesting that 10074-G5 inhibits early aggregation events including oligomerization and multimerization. Error bars represent ± SDs in (A) and (E).
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Materials). Specifically, we first fitted the measured aggregation 
kinetics in the absence of 10074-G5 to a kinetic model of A42 ag-
gregation (see the Supplementary Materials and eq. S11) (38) to 
estimate the values of the unperturbed rates for primary nucleation, 
elongation, and secondary nucleation. We then formulated a master 
equation model for inhibited aggregation kinetics in the presence of 
10074-G5 (eq. S12). We derived explicit integrated rate laws describ-
ing inhibited kinetics (eqs. S12 to S15 and fig. S8), which we used to 
fit the experimental ThT data in the presence of 10074-G5. For this 
analysis, we implemented the unperturbed rate constants for aggre-
gation, leaving the value of Kd as the only fitting parameter. We 
performed a global fit to the normalized data, as described previously 
(44); all ThT profiles at increasing concentrations of 10074-G5 were 
not fit individually, but rather using the same choice of Kd, with the 
dependence of the various rate constants on the concentration of 
10074-G5 being captured in the integrated rate law through eq. S15. 
The result of this global fit, shown in Fig. 5A, accounts for the retar-
dation of aggregation in a global manner using one single parameter 
(Kd) and explains the observed decrease in final fibril load. Furthermore, 
this fit yields an affinity value of Kd = 40 M, consistent with other 
affinities reported for small-molecule binders of disordered proteins 
(22). It is interesting to note that this estimated affinity is considerably 
weaker than small-molecule binders of structured proteins, which 
are often in the nanomolar range. It may seem that such a weak binder 
of A would have little inhibitory effects. However, we note that the 
level of inhibition in general depends not on the absolute value of 
Fig. 5. 10074-G5 inhibits A42 aggregation primarily by monomer sequestration. (A) Global fit of ThT kinetic curves to a monomer sequestration model (eq. S12), in 
which 10074-G5 affects the aggregation by binding free monomers. Measurements are those shown in Fig. 4A. The theoretical curves are obtained using eq. S11 with 
unperturbed kinetic obtained from (B) leaving Kd as the only global fitting parameter (eq. S15). The global fit yields Kd = 40 M. Global fits to eq. S15 were performed on 
normalized data to extract changes in the rate parameters in the presence of 10074-G5. (B) Global fit to eq. S11 and eq. S12 of ThT kinetic traces of the aggregation reac-
tion for increasing concentrations of A42 (1, 1.5, and 2 M) in the absence of 10074-G5. Measurements were taken in duplicate or triplicate. (C) Overlay of theoretical 
kinetic curves from (A) with independent ThT kinetic traces of the aggregation reaction for increasing concentrations of A42 (1, 1.5, and 2 M) in the presence of 10 M 
10074-G5. Solid curves are predictions of the kinetic monomer sequestration model using the same rate parameters and inhibitor binding constant as in (A) and no fitting 
parameters. Measurements were taken in duplicate or triplicate. (D) Effective rates of aggregate proliferation through primary () and secondary () nucleation in the 
presence of varying concentrations of 10074-G5 determined using the global fit in (A). Error bars represent ± SDs in (A to C). (E) Phase diagram illustrating numerical 
solutions to the kinetic equations for different kon and koff rates. Curves represent kinetic aggregation traces of 1 M A42 in the absence (black) and presence of 2 M 
compound (blue). Diagonals correspond to constant values of Kd. The values of k+kn and k2k+ are the same as those shown in (A).
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Kd, but on the combined parameter Kd/[C], where [C] is the drug 
concentration, provided that the rate of binding (kon[C]) is sufficiently 
fast as compared to the overall time scale of aggregation, 1/ (see eq. S11 
for a definition of ) (45). Therefore, it is possible to have effective inhi-
bition even for small molecules with Kd values in the micromolar range, 
provided that [C] is on the same order of magnitude as Kd (see Fig. 5E).
The analysis of experimental aggregation data in the presence of 
increasing concentrations of inhibitor using our integrated rate law 
thus yields an independent method for determining the binding 
constant of 10074-G5 to the monomers. To provide further support 
to this analysis, we varied the concentration of monomeric A42 (1, 1.5, 
and 2 M) and recorded kinetic traces of aggregation in the absence 
(Fig. 5B) and presence of 10 M 10074-G5 (Fig. 5C). Using the rate 
parameters determined from the uninhibited kinetics and the same 
value of Kd obtained from the global fit shown in Fig. 5A, we find 
that the time course of aggregation predicted by our monomer se-
questration model are in good agreement with the independent ex-
perimental data (Fig. 5C).
A key prediction from the monomer sequestration model is that 
a monomer-interacting compound should interfere with all three 
microscopic steps of aggregation. We find that the presence of an 
inhibitor that binds monomers quickly compared to the overall 
aggregation rate does not affect the topology of the reaction network. 
As a result, the inhibited kinetics can be interpreted in terms of ef-
fective rates of aggregation that depend on the concentration of in-
hibitor (eq. S15). In Fig. 5D, we show the values of the effective rates 
of aggregate proliferation through primary () and secondary () 
nucleation pathways as a function of the concentration of 10074-G5 
predicted by this model (see eq. S11 for a definition of  and ). The 
monomer sequestration model also predicts that the effective rate of 
elongation should be reduced, although to a lesser extent than the 
nucleation pathways, which have a stronger monomer concentration 
dependence. To test this prediction, we performed seeded aggregation 
experiments in the presence of preformed A42 fibrils to obtain in-
dependent measurements of the effective elongation rate as a function 
of 10074-G5 concentration. We observed that 10074-G5 indeed de-
creases the effective rate of fibril elongation (fig. S3B), consistent 
with the monomer sequestration mechanism. As our understanding 
of the complex aggregation reaction network of A42 improves, we 
anticipate that more detailed models capable of describing 10074-G5’s 
inhibition will become available, including the ability to account for 
the role of oligomer binding.
We also sought to understand whether 10074-G5 binds mono-
meric A40 with a comparable affinity to that of A42. To address 
this question, we applied the monomer sequestration model as used 
in Fig. 5A to fit the inhibitory effects of 10074-G5 on aggregation of 
10 M A40. From this analysis, we extracted an affinity constant of 
10074-G5 for A40 of 10 M, a similar value to that obtained for 
A42 (fig. S3A). Given the increased toxicity of A42 as compared 
to A40, we anticipate the optimization of small molecules more 
specific for monomeric A42 over A40.
Characterization of the binding of 10074-G5 to stabilized 
A40 oligomers
Next, we probed whether 10074-G5 alters the behavior of oligomeric 
species of A. Although it is extremely challenging to determine 
whether 10074-G5 modifies the oligomeric intermediates of A42 
formed on pathway to aggregation, which are transient, heterogenous 
species, it is possible to carry out this analysis more readily on oligo-
mers of A40 stabilized using Zn2+ (46). Thus, we next considered 
whether or not 10074-G5 can alter the behavior of these stabilized, 
preformed oligomeric species. We incubated preformed oligomers 
in the presence of 10074-G5, centrifuged the samples, and measured 
the quantities of A40 in the pellet and in the supernatant by using 
SDS–polyacrylamide gel electrophoresis (SDS-PAGE, fig. S9A). The 
results indicate that these preformed oligomers did not dissociate in 
the presence of 10074-G5. Furthermore, 10074-G5 was found not to 
alter the turbidity of solutions in which they were present as measured 
by their absorbance profiles (fig. S9B), suggesting that 10074-G5 does 
not cause such species to change detectably in size. Last, dot blots of 
preformed oligomeric samples in the presence and absence of the 
compound using the OC-antibody, which binds to  sheets (47), show 
that the oligomers maintain their characteristic conformations (fig. 
S9C). Because of the colored nature of 10074-G5, it was neither pos-
sible to characterize the oligomers in the presence of the compound 
with dynamic light scattering nor analytical ultracentrifugation 
measurements. Together, these data suggest that 10074-G5 does not 
disaggregate the preformed oligomeric species nor cause them to 
undergo further assembly. Nevertheless, it remains possible that 
this compound affects the evolution of oligomer populations formed 
during the aggregation reaction, potentially inhibiting their conver-
sion into fibril-competent species.
10074-G5 inhibits A42 aggregation in a C. elegans model 
of Alzheimer’s disease
To determine whether 10074-G5 can inhibit the formation of Aβ42 
aggregates in vivo, we tested its effects using a C. elegans model of 
Aβ42-related toxicity (GMC101; Fig. 6 and fig. S10), in which age- 
progressive paralysis was induced by overexpression of Aβ42 in the body 
wall muscle cells (48). The N2 wild-type strain (49) was used as a control.
10074-G5 was administered to worms from larval stage L4, and then 
continuously throughout their lifespan (see Materials and Methods 
and Fig. 6A). First, we quantified the aggregates in the animals by 
means of an amyloid specific fluorescence probe, NIAD-4 (Fig. 6, 
B and C). These results show that the administration of 10074-G5 
resulted in a lower aggregate load. Then, we monitored a number 
of phenotypic readouts of worm health, including body bends 
per minute, the extent of the bending motion, the speed of 
movement, and also the rate of paralysis (shown as the percent of 
worms which move). We found that 10074-G5 improved all of these 
characteristic behavioral parameters in worms expressing A42 in a 
dose-dependent manner when compared to the untreated worms 
(Fig. 6, D and E).
To ensure that 10074-G5 does not affect the expression of A42, 
we performed control experiments using the OW450 strain (50), in 
which the expression of the yellow fluorescent protein (YFP) is con-
trolled by the same gene as the GMC101 strain. We observed that 
treatment with 10074-G5 does not affect YFP fluorescence in live 
animals (fig. S10, B and C) nor levels of YFP in C. elegans lysates 
(fig. S10D). Similarly, we also measured levels of A42 in GMC101 
C. elegans lysates and observed no differences with and without 
treatment of 10074-G5 (fig. S10E).
Together, these results demonstrate that the administration of 
10074-G5 increases the health of this C. elegans model of A42- 
mediated dysfunction and results in the presence of a smaller number 
of amyloid aggregates. These findings are consistent with the obser-
vation of the inhibition of the aggregation of A42 in the presence 
of 10074-G5 from the in vitro studies (Figs. 4 and 5). Furthermore, 
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these results suggest that the combination of in silico, in vitro, and 
in vivo drug discovery methods holds promise for the identification 
of novel small molecules which inhibit the toxic behavior of disease- 
related disordered proteins.
DISCUSSION
We have characterized the binding of the small-molecule 10074-G5 
to monomeric A42 using a combination of experimental approaches 
and integrative structural ensemble determination methods. The real- 
time, dose-dependent responses that we have observed in the BLI 
experiments demonstrate that 10074-G5 binds A42 in its mono-
meric form (Fig. 1B and fig. S1). The NMR experiments and the meta-
dynamic metainference simulations have illustrated that this binding 
is distinct from most small-molecule interactions with structured 
proteins. In particular, we have observed that 10074-G5 does not 
bind to a single binding site, but rather binds transiently to many 
different sites (Figs. 2 and 3, and fig. S6). We have also found 10074-G5 
induces A42 to adopt many different conformations, keeping it 
disordered and more solvent-exposed (Fig. 1, C and D) in the bound form. 
It appears that this interaction is minimally driven by enthalpy, and 
thus is largely entropic (fig. S2, B and C) and that some of this entropy 
arises from the increase in conformational entropy of A42 (Fig. 3) 
via the entropic expansion mechanism (18). This structural insight may 
open new routes for inhibitors of pathogenic disordered proteins and 
small- molecule modulators of liquid-liquid phase separation in-
volving disordered regions. In particular, a greater understanding of 
how one could identify small molecules that alter conformational 
entropy of disordered proteins without extensive off-target effects 
holds great therapeutic potential.
In addition, we have characterized the effects of 10074-G5 on 
amyloid aggregation in vitro using a range of biophysical and kinetic 
theory techniques. This analysis has revealed that as a result of the 
interaction of 10074-G5 with monomeric A42, this small molecule 
also reduces the extent to which monomeric A42 contributes to 
aggregation, thereby effectively slowing down all microscopic aggrega-
tion rates. Our kinetic analysis of aggregation inhibition by monomer 
sequestration highlights that effective inhibition depends on the inter-
play of two combined parameters, namely, a thermodynamic and 
kinetic one: Kd/[C] and kon[C]/ (Fig. 5E) (45). Thus, for a small 
molecule with a given affinity for monomeric A42, increasing the 
kon represents a promising inhibitor optimization strategy. We 
also anticipate future work to understand the relationship between 
kon and the change in conformational entropy of A42 toward im-
proved binders of monomeric disordered proteins. Last, we show 
that 10074-G5 is highly effective at reducing the A42 aggregate 
load and its associated toxicity in a C. elegans model of Alzheimer’s 
disease (Fig. 6).
The results that we have reported indicate the importance of de-
veloping a detailed understanding of the mechanisms of interac-
tion between disordered proteins and small molecules. Increasing 
our knowledge about these mechanisms could lead, in turn, to the 
development of new therapeutic approaches for the many diseases 
in which disordered proteins are involved.
MATERIALS AND METHODS
BLI experiments
A super streptavidin biosensor (FortéBio, Menlo Park, USA) was 
coated with monomeric N-terminally biotinylated A42 (15 g/ml; 
AnaSpec, Fremont, USA) by overnight incubation a solution at 5°C. 
Control biosensors were incubated with the same concentration of 
biocytin. The tips were then rinsed by incubation in buffer for 3 hours 
at room temperature. The binding and dissociation between immo-
bilized A42 and various concentrations of 10074-G5 was monitored 
for 200 and 500 s, respectively, at 37°C using an Octet Red96 (ForteBio, 
Menlo Park, USA). This process was repeated six times (fig. S1, A 
and B). The binding of buffer to a A42-functionalized biosensor 
was subtracted to account for baseline drift. Data were analyzed us-
ing GraphPad Prism 8. Dissociation data were first globally fit using 
a one-phase exponential decay to determine a preliminary koff value. 
This value was then used as an initial input value to determine the 
global kon and koff rates.
2D HN–BESTCON NMR experiments
13C, 15N uniformly labeled, recombinant A42 peptide (the 42-residue 
variant lacking the N-terminal M; see the “Preparation of recombinant 
A peptides” section) was purchased from rPeptide and prepared 
following the manufacturer’s instructions. Twenty micromolar samples 
were prepared in phosphate-buffered saline (PBS) (pH 7.50) and 
Fig. 6. 10074-G5 is effective in reducing functional impairment in a C. elegans 
model of A42 toxicity. (A) Treatment profile used for the C. elegans experiments. 
(B) NIAD-4 staining of C. elegans aggregates in the presence and absence of 5 M 
10074-G5. (C) Quantification of NIAD-4 intensity shown in (B). n ≥ 9. (D) Health scores 
(%) for the rate of body bends, speed of movement, moving percent, and magnitude 
of body bends at day 6 of adulthood. The colors are the same as those shown in (C). 
Scores are normalized to the N2 control strain (gray). n = 150. (E) Combined total 
health scores [average of health scores in (D)]. In all panels, error bars represent ± 
SEM. P values were determined by two-tailed Student’s t test. 10074-G5 shows 
minimal movement effects on wild-type C. elegans (fig. S10).
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1% dimethyl sulfoxide (DMSO), with 5% D2O (Sigma-Aldrich) for 
the lock. 2D HN–BESTCON measurements (25) were performed at 
16.4 T on a Bruker Avance spectrometer operating at 700.06 MHz 
1H, 176.03 MHz 13C, and 70.9 MHz 15N frequencies, equipped with 
a triple-resonance cryogenically cooled probehead optimized for 
13C-direct detection (at the Centro di Risonanze Magnetiche, Flor-
ence, Italy). Each 2D HN–BESTCON spectrum was acquired with 64 
scans. The dimensions of the acquired data were 1024 (13C) × 116 
(15N) points. The spectral width was 29.9 × 33.9 ppm for F2 and F1, 
respectively. The relaxation delay was set to 0.3 s. 2D HN–BESTCON 
measurements were repeated with the same parameters except for 
the inclusion of a weak presaturation of the solvent signal during 
the relaxation delay. Under these conditions, signals of amide nitrogen 
whose directly bound protons are in fast exchange with the solvent are 
attenuated. This approach was tested on a well-characterized protein 
(ubiquitin) and then used for the study of the A42 peptide with 
and without the addition of 10074-G5. 1D 1H and 2D BEST TROSY 
(51) spectra were acquired before and after measurements were taken 
to ensure that minimal aggregation had occurred during the course 
of the measurement. Experimental data were acquired at 5° and 15°C 
using Bruker TopSpin 3.1 software and processed with Sparky 3.115.
Metadynamic metainference simulations
To generate the structural ensembles, we used an integrative approach 
that incorporates NMR chemical shift data into molecular dynamics 
simulations. To this end, we used metadynamic metainference, which 
compensates for the inaccuracies of the force field, accounts for errors 
in experimental data, and enhances sampling (28, 29). All-atom 
metadynamic metainference simulations (28) of the unbound and 
bound form of A42 were performed using GROMACS 2018.3 (52) 
patched with PLUMED library 2.6.0-dev (git: 0edcfb268569) (53), 
the CHARMM22* force field (54), and TIP3P water model (55). The 
initial conformation of A42 was prepared as a linear peptide using 
PyMOL (https://pymol.org/2/). A preliminary in vacuo molecular 
dynamics simulation was performed for 1 ns to collapse the extend-
ed conformation. This structure was solvated in a rhombic do-
decahedron box with an initial volume of 362  nm3 containing 
11,746 water molecules. The solvated system was minimized using 
the steepest descent algorithm with a target maximum force of 1000 kJ 
mol−1 nm−1. A pool of 48 initial conformations was extracted from 
a preliminary 2-ns simulation at 600 K in the NVT ensemble. Equili-
bration was then performed in the canonical (NVT) ensemble for 500 ps 
at 278 K using the Bussi-Donadio-Parrinello thermostat (56) and for 
500 ps at 278 K in the isothermal-isobaric (NPT) ensemble using 
Berendsen pressure coupling (57) with position restraints on heavy 
atoms. Production runs were executed in the NPT ensemble at 278 K 
using the Parrinello-Rahman barostat (58). A time step of 2 fs was 
used together with LINCS constraints on all bonds (59). The van der 
Waals interactions were cut off at 1.2 nm, and the particle-mesh Ewald 
method was used for electrostatic interactions (60). Bound simulations 
were performed as described above, using the starting structures ob-
tained from the NVT equilibration at 600 K. The 10074-G5 molecule 
was added to a corner of the box and the system resolvated with 
11,734 water molecules. The system was then minimized and equili-
brated using the procedures described above. Preliminary parameters 
for 10074-G5 were taken from the CGenFF software (61), and those 
with any penalty were explicitly reparameterized using the Force Field 
Toolkit (62) and Gaussian 09 (www.gaussian.com) (see the Supple-
mentary Materials and fig. S4).
Chemical shifts were back calculated at each time step using 
CamShift (fig. S5) (63). Given that the error of the CamShift predictor 
is greater than the chemical shift perturbations upon addition of the 
compound, the same chemical shifts were used to restrain both the 
unbound and bound simulations. A Gaussian noise model with one 
error parameter per nucleus type was used in the metainference setup, 
along with an uninformative Jeffreys prior for each error parameter 
(see the Supplementary Materials) (28). The metainference ensem-
bles for the unbound and bound simulations were simulated using 
48 replicas each.
Parallel bias metadynamics (64) with the well-tempered (65) and 
multiple-walker (66) protocols were performed using a Gaussian 
deposition stride of 1 ps, an initial height of 1.2 kJ/mol, and bias 
factors of 24 and 49 for the unbound and bound simulations, re-
spectively. In the unbound simulations, we used six collective variables 
(CVs) to enhance the conformational sampling of A42 (see the 
Supplementary Materials). In the bound simulations, we also included 
14 CVs to enhance the conformational sampling of contacts between 
the compound and the peptide and four CVs to enhance sampling of 
soft dihedrals in the small molecule (see the Supplementary Materials). 
Unbound and bound simulations were run for an accumulated time 
of 27.8 and 28.2 s, respectively, until convergence was reached (see 
the Supplementary Materials and Fig. 3C). For details on the analysis, 
see the Supplementary Materials.
Preparation of recombinant A peptides
Recombinant A(M1-42) (MDAEFRHDSGY EVHHQKLVFF 
AEDVGSNKGA IIGLMVGGVVIA) and A(M1-40) (MDAEFRHDSGY 
EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV), here, referred 
to as A42 and A40, respectively, were prepared by expression in 
Escherichia coli BL21 (DE3) Gold Strain (Agilent Technologies, Santa 
Clara, USA) (37). The resulting inclusion bodies were dissolved in 
8 M urea, ion exchanged in batch mode on diethylaminoethyl cellulose 
resin, lyophilized, and then further purified with a Superdex 75 HR 
26/60 column (GE Healthcare, Chicago, USA). Fractions containing 
the recombinant protein, as determined by SDS-PAGE, were com-
bined and lyophilized again. To ensure we were working with high-
ly purified monomeric species containing extremely low quantities of 
aggregated forms of the peptides, size exclusion chromatography 
was carried out directly before the experiments were performed. A40 
and A42 solutions were prepared by dissolving the lyophilized 
peptide in 6 M GuHCl and incubating on ice for 3 hours. The solu-
tions were then purified using a Superdex 75 Increase 10/300 GL 
column (GE Healthcare, Chicago, USA) at a flow rate of 0.5 ml/min 
and eluted in 20 mM sodium phosphate buffer (pH 8) supplemented 
with 200 M EDTA. The center of the peak was collected, and the 
concentrations of the peptides were determined from the integration 
of the absorbance peak using 280 = 1495 L mol−1 cm−1.
Preparation of small molecules
10074-G5 was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
The molecules were dissolved in 100% DMSO and then diluted in 
solutions of A40 or A42 to reach a maximum final DMSO con-
centration of 1.5%. The total DMSO concentration was matched in 
the control solutions in all experiments.
ThT aggregation kinetics
Monomeric A40 or A42 were diluted with buffer and 20 M ThT 
from a 2 mM stock and increasing amounts of 10074-G5. Samples 
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were prepared using LoBind Eppendorf tubes (Sigma-Aldrich, MO, 
St. Louis, USA) on ice. Fibrils for seeding experiments were prepared 
by incubating monomeric A42 at 37°C overnight. The concentration 
of fibrils (in monomer equivalents) was assumed to be the initial 
concentration of monomer. These preformed fibrils were added to 
a freshly prepared monomer solution to give a final concentration 
of 15% fibrils.
Samples with or without seed fibrils were pipetted into multiple 
wells of a 96-well half-area, low-binding polyethylene glycol coating 
plate (Corning 3881, Sigma-Aldrich) with a clear bottom, at 90 l per 
well. Plates were sealed with aluminum sealing tape (Corning, Sigma- 
Aldrich) to prevent evaporation and then placed at 37°C under qui-
escent conditions in a plate reader (CLARIOstar; BMG Labtech, Ortenberg, 
Germany). ThT fluorescence was measured through the bottom of 
the plate using 440- and 480-nm excitation and emission filters, re-
spectively. ThT fluorescence was followed with multiple replicates 
as specified in the corresponding figure captions. For analysis of 
ThT kinetics see the Supplementary Materials.
Mass spectrometry
Monomeric A42 was diluted in the aggregation buffer (described 
above) to a concentration of 15 M in the presence and absence of 
30 M 10074-G5. Samples were incubated overnight at 37°C under 
quiescent conditions to mimic the aggregation experiments. The 
samples were then spun down using an ultracentrifuge at 100,000 rpm 
for 1 hour at 25°C to separate the supernatant and pellet. GuHCl (6 M) 
was used to dilute the supernatant by 50% and resuspend the pellet. 
Samples were analyzed by MALDI mass spectrometry at the Protein 
and Nucleic Acid Chemistry Facility at the Department of Bio-
chemistry, University of Cambridge.
Dot-blot assay
Blotting was performed using the A42 sequence-specific antibody 
(W0-2, MABN10, Millipore, Burlington, USA). Samples were re-
moved from a solution containing 2 M A42 in the presence and 
absence of 3- and 10-fold equivalence of 10074-G5. To ensure only 
the monomer was placed on the blots, samples were spun down using 
an ultracentrifuge at 100,000 rpm for 1 hour at 25°C using a TLA100 
rotor. Two microliters of the supernatant was pipetted onto a nitro-
cellulose membrane (0.2 M; Whatman). After drying, the mem-
brane was blocked with 5% (w/v) bovine serum albumin (BSA) in 
PBS [8 mM Na2HPO4, 15 mM KH2PO4, 137 mM NaCl, 3 mM KCl 
(pH 7.4), and PBS] overnight at 5°C, followed by three 15-min washes 
with PBS at room temperature. The membrane was then immunized 
with a 1:1000 dilution of WO-2 anti-A antibody in PBS with 5% 
BSA overnight at 5°C, followed by three 15-min washes with PBS at 
room temperature. The membrane was then incubated for 2 hours 
at room temperature in PBS supplemented with 0.05% Tween 20 and 
an anti-mouse–Alexa Fluor 594 secondary antibody conjugate (Thermo 
Fisher Scientific, Waltham, USA) at room temperature and then 
washed three times with PBS supplemented with 0.05% Tween 20. Fluo-
rescence detection was performed using Typhoon Trio Imager (GE 
Healthcare, Chicago, IL, USA). Blots were quantified using ImageJ. 
Data were fit to a competitive binding equilibrium model between 
free monomers and fibrils (eq. S14). In this model, monomers are 
either free, aggregated (i.e., part of a fibril), or bound to 10074-G5; 
the binding of the compound to the monomer is described by a single- 
binding free energy. The binding of monomers to fibril ends is 
stronger compared to the binding of monomers to the inhibitor. The 
concentration of free monomer in equilibrium with amyloid fibrils (crit-
ical concentration) measured in our experiments was mcritical = 93 nM, 
consistent with other reports (67). The equilibrium concentration 
of unreacted soluble monomer after ultracentrifugation measured 
at varying inhibitor concentrations was fit to eq. S14 with Kd as a 
fitting parameter. This procedure yields Kd = 7 ± 1 M, as shown 
in Fig. 4E.
Atomic force microscopy
Solutions of 1 M A42 in the presence and absence of 6 M 10074-G5 
were deposited on mica positively functionalized with (3-aminopropyl) 
triethoxysilane (APTES; Sigma-Aldrich, St. Louis, USA) in the ab-
sence of ThT. The incubation times were selected on the basis of the 
results of the chemical kinetics experiments. The mica substrate was 
positively functionalized by incubation with a 10-l drop of 0.05% 
(v/v) APTES in Milli-Q water for 1 min at ambient temperature, 
rinsed with Milli-Q water, and then dried by the passage of a gentle 
flow of gaseous nitrogen (42). AFM sample preparation was carried 
out at room temperature by deposition of a 10-l drop of protein 
solution deposited for 2 min to a surface treated with APTES. The 
samples were rinsed with Milli-Q water, dried with nitrogen gas, 
and stored in a sealed container until imaging. AFM maps were ac-
quired by means of a NX10 (Park Systems, Suwon, Korea) and a 
nanowizard2 (JPK Instruments, Berlin, Germany) system operating 
in tapping mode and equipped with a silicon tip (PPP-NCHR and 
masch) with a nominal radius of 10 nm. Image flattening and single 
aggregate statistical analysis were performed by SPIP 6 (Image 
Metrology, Hørsholm, Denmark) software.
Isothermal titration calorimetry experiments
Measurements were performed using an MicroCal Auto-ITC 200 
(GE Healthcare, Chicago, USA) at 15°C. Because of the poor solu-
bility of 10074-G5, monomeric A40 (200 M) was injected 10 times 
into a solution containing 7 M 10074-G5. All solutions were pre-
pared in phosphate buffer (described above) and contained a minimal 
amount of DMSO (0.2%) to ensure that the compound was soluble. 
Each injection was 3.5 l in volume and was made on 3-min inter-
vals. Heats of dilution, obtained by separately injecting the peptide 
into buffer and buffer into the solution containing 10074-G5, were 
subtracted from the final data. The corrected heats were divided by 
the number of moles injected and analyzed using Origin 7.0 software 
(OriginLab, Northampton, USA).
Characterization of the interaction of 10074-G5 
with stabilized oligomers
Stabilized oligomers were formed from A40 as previously described 
(46). Briefly, 1 mg of lyophilized A40 was dissolved in 300 l of 
hexafluoroisopropanol and incubated overnight at 4°C. After solvent 
evaporation under nitrogen gas, A40 was resuspended in DMSO 
to a concentration of 2.2 mM and sonicated twice for 10 min at room 
temperature. The protein sample was diluted to a final concentra-
tion of 100 M in 20 mM sodium phosphate buffer with 200 M 
ZnCl2 at pH 6.9. After incubation for 20 hours at 20°C, the solution 
was centrifuged for 15 min at 15,000g at room temperature. The 
pellet containing the oligomers was resuspended in 20 mM phos-
phate buffer at pH 6.9, with 200 M ZnCl2.
Samples containing 20 and 10 M preformed Zn2+-stabilized A40 
oligomers were incubated in the presence and absence of 20 M 
10074-G5 for 1 hour. The turbidimetries of the samples were analyzed 
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using a plate reader (BMG Labtech, Aylesbury, UK) at 600 nm. Mea-
surements were background subtracted against buffer alone in the 
absence and presence of compound. The protein content within 
samples was quantified using the sequence-specific WO-2 antibody 
(see the “Dot-blot assay” section). Similarly, the conformations of 
the oligomers in the presence and the absence of the compound was 
probed using the conformation-specific OC antibody (47) (AB2286, 
Millipore, Burlington, USA) using the protocols described above 
(see the “Dot-blot assay” section).
To determine whether the oligomers had dissociated after the 
incubation in the presence of the compound, the samples were centri-
fuged for 15 min at 15,000g. The pellet was resuspended in 15 l of 
20 mM phosphate buffer at pH 6.9 with 200 M ZnCl2 and analyzed 
along with the supernatant by SDS-PAGE.
C. elegans experiments
The following C. elegans strains were used: the temperature-sensitive 
human A-expressing strain dvIs100 [unc-54p:: A-beta-1–42::unc-54 
3′-UTR + mtl-2p::GFP] (GMC101), where mtl-2p::GFP causes in-
testinal GFP expression, and unc-54p::A1–42, which expresses the 
human full-length A42 peptide in the muscle cells of the body wall. 
Raising the temperature above 20°C at the L4 or adult stage causes 
paralysis due to A42 aggregation in body wall muscle (48). The N2 
wild-type strain was used as a control (48, 49).
Standard conditions were used for the propagation of C. elegans 
(48); the animals were synchronized by hypochlorite bleaching, 
hatched overnight in M9 [KH2PO4 (3 g/liter), Na2HPO4 (6 g/liter), 
NaCl (5 g/liter), and 1 M MgSO4] buffer, and subsequently cultured 
at 20°C on nematode growth medium (NGM) [1 mM CaCl2, 1 mM 
MgSO4, cholesterol (5 g/ml), 250 M KH2PO4 (pH 6), agar (17 g/liter), 
NaCl (3 g/liter), and casein (7.5 g/liter)] plates seeded with the E. coli 
strain OP50. Saturated cultures of OP50 were grown by inoculating 
50 ml of LB (Luria Broth) medium [tryptone (10 g/liter), NaCl 
(10 g/liter), and yeast extract (5 g/liter)] with OP50 and incubating 
the culture for 16 hours at 37°C. NGM plates were seeded with 
bacteria by adding 350 l of saturated OP50 to each plate and leaving 
the plates at 20°C for 2 to 3 days. On day 3 after synchronization, the 
animals were placed on NGM plates containing 5-fluoro-2’deoxy- uridine 
(FUDR) (75 M, unless stated otherwise) to inhibit the growth of offspring.
NGM plates containing FUDR (75 M) were seeded with 350 l 
of OP50 culture and grown overnight. After incubating for up to 
3 days at room temperature, 2.2-ml aliquots of 10074-G5 dissolved 
in 1% DMSO at different concentrations were spotted atop the 
NGM plates. The plates were then placed in a sterile laminar flow 
hood at room temperature to dry. For the final experiments, worms 
were transferred onto the 10074-G5–seeded plates directly at larval 
stage L4, and they were exposed to 10075-G5 for the whole duration 
of the experiment.
To ensure that the presence of 10074-G5 did not affect the OP50 
E. coli consumed by the C. elegans, we performed a growth assay of 
the E. coli directly from the NGM plates in the presence of 10074-
G5 or DMSO after 1 day of incubation at 24°C (fig. S10A). E. coli from 
the NGM plates were added to 4 ml of LB media and diluted to an 
optical density of 0.25. Then, 3 ml of this starter culture was added 
to 40 ml of sterile LB media, which was incubated at 37°C and shaking 
at 180 rpm. Optical density measurements were collected every 
30 min, and the experiment was performed in duplicate.
All C. elegans populations were cultured at 20°C and develop-
mentally synchronized from a 4-hour egg lay. At 64 to 72 hours after 
egg lay (time zero), individuals were transferred to FUDR plates and 
cultured at 24°C to stimulate aggregation, and body movements were 
assessed over the times indicated. At different ages, the animals were 
washed off the agar plates with M9 buffer and spread over an OP50 
unseeded 9-cm plate. The swimming worms were visualized by using 
a high-performance imaging lens and a machine vision camera, after 
which their movements were recorded at a high number of frames 
per second (fps) for 30 s or 1 min (68, 69). Body bends were then 
quantified using a tracking algorithm (69, 70). Briefly, after an initial 
background subtraction, a second (nonadaptive) thresholding pro-
cedure was performed, and worms were identified and labeled. The 
eccentricity, a measure of the ratio of the minor and major ellipse 
axes, of each tracked worm was then used to estimate the worm 
bending as a function of time (69, 70). The total health was calculated 
by averaging the mobility, speed, bend measure, and viability of the 
worms (69, 70). Total health values were normalized using the values 
of the control worms. At least 150 animals were examined per con-
dition, unless stated otherwise. All experiments were carried out in 
triplicate, and the data from one representative experiment are shown 
in Fig. 6. Control experiments to test the effects of 10074-G5 on the 
movement of N2 wild-type C. elegans are shown in fig. S10 (F and G). 
Two-tailed Student’s t tests (unpaired) were used to calculate P values. 
Statistical analysis was performed using the GraphPad Prism 6 software.
To ensure 10074-G5 did not alter the function of unc-54p, we 
performed control experiments using the rmIs126 [P(unc-54)
Q0::YFP]V (OW450) strain (50). In this strain, the YFP is expressed 
and remains diffusely localized throughout aging. OW450 C. elegans 
were treated in the presence and absence of 5 M 10074-G5. Live 
transgenic animals were imaged using Cell Culture plates (Nunc 
MicroWell 96-Well, catalog no. 165305, Thermo Fisher Scientific) 
and immobilized using 40 mM NaN3 as anesthetic. Images were 
captured with an EVOS M7000 fluorescence microscope (Thermo 
Fisher Scientific) with a 10× objective and a YFP filter. Over 100 
worms were analyzed per condition. One representative image per 
condition is shown (fig. S10B). The average fluorescence intensity 
per worm (fig. S10C) was calculated using ImageJ software (National 
Institutes of Health). In addition, more than 1000 OW450 animals 
per condition were frozen in S basal in liquid N2, thawed, and resus-
pended in 500 l of PBS supplemented with one cOmplete Mini 
EDTA-free Protease Inhibitor Cocktail tablet (Roche). Animals were 
then sonicated five times for 45 s (50% cycles at 50% maximum power) 
on ice with a Bandelin Sonopuls HD 2070 sonicator, followed by 
15 min of centrifugation at maximal speed using a bench centrifuge. 
The supernatant (2.5 l) was spotted onto nitrocellulose membranes 
in triplicate and probed using a 1:1000 dilution of the anti-YFP pri-
mary antibody (Bio-Rad) using the protocols described above (see 
the “Dot-blot assay” section). To ensure standard protein loading, 
parallel blots were probed using an anti–-tubulin antibody (Abcam) 
(fig. S10D). Similarly, the amount of A in treated and untreated 
GMC101 C. elegans were quantified as described above using a 1:1000 
dilution of the A sequence-specific WO-2 antibody (see the “Dot-blot 
assay” section and fig. S10E). Approximately 5000 worms were used 
per condition.
To stain the aggregates within the C. elegans, live transgenic animals 
were incubated with 1 M NIAD-4 (0.1% DMSO in M9 buffer) for 
4 hours at room temperature (9). After staining, animals were al-
lowed to recover on NGM plates for about 24 hours to allow de-
staining via normal metabolism. Stained animals were mounted on 
2% agarose pads containing 40 mM NaN3 as an anesthetic on glass 
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microscope slides for imaging. Images were captured with a Zeiss 
Axio Observer D1 fluorescence microscope (Carl Zeiss Microscopy 
GmbH, Jena, Germany) with a 20× objective and a 49004 ET-CY3/
TRITC filter (Chroma Technology Corp, Bellows Falls, USA). Fluo-
rescence intensity was calculated using ImageJ software (National 
Institutes of Health) and then normalized as the corrected total fluo-
rescence (9, 71). Only the head region was considered because of the 
high background signal in the intestinal regions. At least 9 animals 
were examined per condition.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/45/eabb5924/DC1
View/request a protocol for this paper from Bio-protocol.
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